A Physiologically Based Pharmacokinetic Model to Predict Determinants of Variability in Epirubicin Exposure and Tissue Distribution

Background: Epirubicin is an anthracycline antineoplastic drug that is primarily used in combination therapies for the treatment of breast, gastric, lung and ovarian cancers and lymphomas. Epirubicin is administered intravenously (IV) over 3 to 5 min once every 21 days with dosing based on body surf...

Descripción completa

Detalles Bibliográficos
Autores principales: Ansaar, Radwan, Meech, Robyn, Rowland, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143085/
https://www.ncbi.nlm.nih.gov/pubmed/37111707
http://dx.doi.org/10.3390/pharmaceutics15041222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143085/
https://www.ncbi.nlm.nih.gov/pubmed/37111707
http://dx.doi.org/10.3390/pharmaceutics15041222

Ejemplares similares